{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:32:03Z","timestamp":1768415523725,"version":"3.49.0"},"reference-count":25,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)\/SOF were launched in 2016. Patients who achieve a sustained virologic response (SVR) following DAA treatment are predicted to have a favorable prognosis. Nevertheless, little is known regarding the prognosis of Korean CHC patients who receive SOF-based treatment and achieve SVR. Therefore, the purpose of this study was to look into the long-term outcomes for these patients. Materials and Methods: This was a prospective, multicenter observational study. CHC patients were enrolled who, following SOF or LDV\/SOF treatment, had achieved SVR. The last day for follow-up was December 2023. The primary endpoint was HCC occurrence, which was checked at least once per year. Results: A total of 516 patients were included in this analysis, with a median follow-up duration of 39.0 months. Among them, 231 were male patients (44.8%), with a median age of 62.0 years. Genotypes were 1 (90, 17.4%), 2 (423, 82.0%), and 3 (3, 0.6%). The combination of SOF plus ribavirin was the most common treatment (394, 76.4%). In total, 160 patients were cirrhotic (31.0%), and the mean Child\u2013Pugh score was 5.1. Within a maximum of 7 years, 21 patients (4.1%) developed HCC. Patients with HCC were older (69 vs. 61 years, p = 0.013) and had a higher cirrhosis incidence (81.0 vs. 28.9%, p &lt; 0.001), higher AFP (6.0 vs. 3.3, p = 0.003) and higher APRI (0.8 vs. 0.5, p = 0.005). Age over 65 (p = 0.016) and cirrhosis (p = 0.005) were found to be significant risk factors for HCC by Cox regression analysis. Conclusions: Patients who achieved SVR with SOF-based treatment had a relatively favorable prognosis. However, the risk of HCC was not eliminated, especially in older and cirrhotic patients. Therefore, routine follow-up, surveillance, and early treatment are required.<\/jats:p>","DOI":"10.3390\/medicina60071132","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:35:17Z","timestamp":1721032517000},"page":"1132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years"],"prefix":"10.3390","volume":"60","author":[{"given":"Yewan","family":"Park","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-0233","authenticated-orcid":false,"given":"Seong-Kyun","family":"Na","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-2496","authenticated-orcid":false,"given":"Jae-Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Chonnam National University Hospital, Gwangju 61469, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6236-780X","authenticated-orcid":false,"given":"Sung-Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hallym University College of Medicine, Anyang 14068, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-9993","authenticated-orcid":false,"given":"Ji-Won","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hallym University College of Medicine, Anyang 14068, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-Ae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-0859","authenticated-orcid":false,"given":"Young-Sun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Korea University Medical Center, Seoul 08308, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8383-8524","authenticated-orcid":false,"given":"Jeong-Han","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of Korea"},{"name":"Research Institute of Medical Science, Konkuk University School of Medicine, Seoul 05029, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,14]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, March 18). Elimination of Hepatitis by 2030. Available online: https:\/\/www.who.int\/health-topics\/hepatitis\/elimination-of-hepatitis-by-2030#tab=tab_1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3350\/cmh.2021.0236","article-title":"A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3350\/cmh.2021.0193","article-title":"Cost-effectiveness of chronic hepatitis C screening and treatment","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated with Direct Acting Antiviral Agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease Progression in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents","volume":"18","author":"Mendizabal","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zou, Y., Yue, M., Jia, L., Wang, Y., Chen, H., Zhang, A., Xia, X., Liu, W., Yu, R., and Yang, S. (2023). Accurate prediction of HCC risk after SVR in patients with hepatitis C cirrhosis based on longitudinal data. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11628-1"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s12072-020-10105-2","article-title":"HCC risk post-SVR with DAAs in East Asians: Findings from the REAL-C. cohort","volume":"14","author":"Tanaka","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.5009\/gnl19260","article-title":"Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose","volume":"14","author":"Jang","year":"2020","journal-title":"Gut Liver"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3904\/kjim.2022.013","article-title":"Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: A multicenter cohort study","volume":"37","author":"Lee","year":"2022","journal-title":"Korean J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol., 69, 461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"70","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2017.11.009","article-title":"Real-world effectiveness of 8-week treatment with ledipasvir\/sofosbuvir in chronic hepatitis C","volume":"68","author":"Buggisch","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","article-title":"Real-world effectiveness of ledipasvir\/sofosbuvir in 4365 treatment-naive, genotype 1 hepatitis C-infected patients","volume":"64","author":"Backus","year":"2016","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What Are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis Regression After Eradication of Hepatitis C Virus: From bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","article-title":"Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study","volume":"58","author":"Ogawa","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2023.05.042","article-title":"Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals","volume":"79","author":"Minami","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_24","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., and Lo Re, V. (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12072-016-9736-3","article-title":"APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol. Int."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:16:32Z","timestamp":1760109392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,14]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["medicina60071132"],"URL":"https:\/\/doi.org\/10.3390\/medicina60071132","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,14]]}}}